GlassScriptPhysician profile
Cheryl I Baker
NPI 1205050028
$2,973.77
in general payments reported to CMS, 2019-2025
19 companies · $1,504 in 2025
The $1,504 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $190 · 2023: $366 · 2024: $914 · 2025: $1,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,783.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $455.47 | 2021-2025 | Rybrevant, Carvykti |
| Lilly USA, LLC | $355.54 | 2024-2025 | Jaypirca |
| Astrazeneca Pharmaceuticals LP | $296.34 | 2025 | Datroway, Tagrisso |
| Daiichi Sankyo INC. | $271.16 | 2023-2025 | Enhertu, Injectafer |
| Astellas Pharma US INC | $253.53 | 2024-2025 | Vyloy |
| Merck Sharp & Dohme LLC | $250.00 | 2023-2024 | Keytruda |
| Novartis Pharmaceuticals Corporation | $182.11 | 2021-2025 | |
| Pfizer INC. | $138.02 | 2021-2025 | |
| Sobi, INC | $129.13 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Opdivo |
| Glaxosmithkline, LLC. | $117.85 | 2025 | Ojjaara |
| Genmab U.S., INC. | $115.74 | 2024 | Tivdak |
| Regeneron Healthcare Solutions, INC. | $113.62 | 2025 | Libtayo |
| Stemline Therapeutics INC. | $50.94 | 2025 | Orserdu |
| Emd Serono, INC. | $29.02 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $26.66 | 2023 | Qinlock |
| Novo Nordisk INC | $22.09 | 2021 | |
| Taiho Oncology, INC. | $21.33 | 2024 | |
| Genzyme Corporation | $20.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.